Meet the Burridge lab team members. We welcome requests for information about our work and collaboration opportunities.
Paul Burridge, PhD
Assistant Professor, Department of Pharmacology and Center for Pharmacogenomics
Dr. Burridge is an assistant professor in the Department of Pharmacology at Northwestern University Feinberg School of Medicine and a founding faculty member of the Center for Pharmacogenomics. Dr. Burridge began his career in genomics and bioinformatics at the Sanger Institute working on the human and mouse genome projects. He completed a PhD in Human Stem Cell Biology at the University of Nottingham before pursuing postdoctoral fellowships at the Johns Hopkins University in Pediatric Oncology and then at Stanford University in Cardiology before becoming an Instructor in Cardiovascular Medicine at Stanford. For more than 15 years, Dr. Burridge has worked on the applications of human pluripotent stem cells (both hESC and hiPSC), concentrating on culture and differentiation methodologies, regenerative medicine, and disease modeling, specifically the pharmacogenomic and molecular mechanisms of chemotherapy-induced cardiomyopathy and heart failure. Dr. Burridge is the recipient of the NIH NHLBI Pathway to Independence Award and a Fellow of the American Heart Association in Genomic and Precision Medicine.
View Northwestern University Feinberg School of Medicine faculty profile
Ansel Philip Amaral, MD, PhD
Ansel earned his PhD in Molecular Cell and Developmental Biology from the Leonard M. Miller School of Medicine at the University of Miami. His thesis work focused on the role of growth factors in the development of left ventricular hypertrophy. He was a member of the Medical Scientist Training Program (MD/PhD) and after completion of medical school, he was accepted to the Physician Scientist Training Program at the Feinberg School of Medicine at Northwestern University. Ansel has completed residency in Internal Medicine and is currently a clinical fellow in Cardiology. He began his postdoctoral research in the Burridge Lab in the summer of 2018, where he focuses on hiPSC models of heart failure and drug efficacy.
Malorie Blancard, PhD
Training: Malorie earned her PhD in Human Genetics from Sorbonne University in Paris in 2018. There, she focused on the identification of new variants causing cardiac arrhythmias with a risk of sudden death by using exome sequencing analysis and functional studies on calcium channels. She is interested to pursue her career on rare cardiac arrhythmias using other relevant technologies such as genome sequencing and hiPSC. She started her first postdoctoral research in Burridge Lab in February of 2019 and works on hiPSC models of sudden cardiac death.
Hananeh Fonoudi, PhD
Training: Hananeh earned her PhD in Stem Cells and Developmental Biology from the St. Vincent’s Clinical School of Medicine at the University of New South Wales, Sydney, Australia. During her PhD work she studied the genetics of hypoplastic left heart syndrome (HLHS) using human induced pluripotent stem cells under supervision of Dr. Richard Harvey at the Victor Chang Cardiac Research Institute. She joined Burridge lab at Northwestern University in February 2019 and works on human cardiac organoids and modeling pediatric congenital heart disease.
Mariam Jouni, PhD
Mariam earned her PhD. in Electrophysiology and Stem cell biology in 2015 from the University of Nantes in France. During her PhD, she worked at L'unité de recherche de l'institut du thorax and got trained to perform electrophysiological characterization of hiPSC-derived cardiomyocytes. She was further interested in translational medicine, so following her PhD., she started her first postdoctoral fellowship at UHN, Toronto General Hospital under the supervision of Dr. Michael Laflamme. She joined Burridge Lab at Northwestern University in July 2018 and works on novel variants causing long QT syndrome.
Tarek Mohamed, PhD
Tarek Mohamed earned his PhD in pharmacogenomics from the School of Pharmacy, Eberhard Karls University of Tuebingen in Germany. While earning his PhD, he worked as an early-stage researcher within a European Union sponsored research programme entitled “FightingDrugFailure” as a part of Marie Curie Initial Training Network (ITN) at the Dr. Margarete Fischer-Bosch institute of clinical pharmacology in Stuttgart, Germany. He started his postdoctoral studies in Burridge Lab at Northwestern University in September of 2015.
Deborah Sung, MD
Clinical Research Fellow
Deborah earned her MD from the University of Washington School of Medicine and went on to complete her residency and chief resident year in Pediatrics at The Children's Hospital at Montefiore/Albert Einstein College of Medicine. She is currently a Pediatric Critical Care Fellow at Ann & Robert H. Lurie Children's Hospital of Chicago. She joined the Burridge Lab in 2017 and is interested in the application of precision medicine in cardiovascular disease.
Mennat Gharib, BS
Hoor Javed, BS
Hoor Javed earned her BS in Neuroscience at the University of Illinois at Chicago (UIC) and graduated with Magna cum laude in 2019. During her undergraduate studies, she worked as a Research Assistant in the department of physiology and biophysics at UIC College of medicine. She joined Burridge Lab in July 2019 and is an aspiring healthcare professional with an interest in medicine.
K. Ashley Fetterman, BA
PhD Student (DGP)
Ashley is a PhD student in the Driskill Graduate Program (DGP) at Northwestern. She received her BA in Biological Sciences from Mount Holyoke College. Before joining the Burridge lab, she worked in drug discovery and clinical research. She is focusing on calmodulinopathies, chemotherapy-induced arrhythmias, cardiomyocyte subtype specification, and maturation in the Burridge lab.
Emily Pinheiro, BA
MD/PhD Student (MSTP)
Emily is an MD/PhD student in the Medical Scientist Training Program and Driskill Graduate Program (DGP) at Northwestern University. She received her B.A. from the University of Illinois at Urbana-Champaign. Before joining the Burridge lab, she worked in clinical research with a focus on pharmacotherapy for pregnant women. Her current project uses a pluripotent stem cell-derived model to study nilotinib-induced peripheral artery disease.
Marisol Romero Tejeda, AB
PhD Student (DGP)
Marisol is a PhD student in the Driskill Graduate Program (DGP) at Northwestern University. She received her AB in Human Developmental and Regenerative Biology from Harvard University. Before joining the Burridge lab, she worked as a technician at the Ragon Institute of MGH, MIT, and Harvard. She currently works on direct reprogramming.
Carly Weddle, BS
PhD Student (DGP)
Carly is a PhD student in the Driskill Graduate Program (DGP) at Northwestern, where she is studying hiPSC models of breast cancer. She received her BS in Biochemistry from Elon University while conducting research in analytical chemistry.
Conrad Epting, MD
Attending Physician, Critical Care and Cardiology, Associate Professor of Pediatrics and Pathology
Strategies to promote cell and tissue regeneration remain at the forefront of cardiovascular biology. I have a scientific background in myogenic stem cells and skeletal muscle regeneration. At Northwestern University, I spent some years studying myocardial targeting by pathogens, specifically T. cruzi, the leading cause of myocarditis and heart failure in endemic regions of Latin American. However, as a practicing cardiac intensivist, my research program has shifted to the study of pediatric heart failure. I am interested in the response of resident progenitor cells to aging and heart failure. We suspect an epigenetic basis for cardiac progenitor cell activation in patients with premature ventricular failure secondary to exposure from neurohormonal axis activation. In partnership with the pediatric cardiovascular surgeons we created a cardiac biorepository to further translational research across the institution. Through collaboration with the Burridge laboratory I hope to determine the differentiation potential of resident cardiac cell populations and optimize direct reprograming of primary cardiac fibroblasts. We hope that knowledge of the phenotype of resident cells and their reprograming potential will enable clinical cryobanking, ex vivo reprogramming, and in situ cell manipulation to extend the lives of children and young adults with progressive heart failure from cardiomyopathy and congenital heart disease. We have implementing the Fontan Futures Initiative to optimize atrial tissue cryopreservation and enable clinical grade biobanking on behalf of patients with single ventricle physiology who are likely to progress to end-stage heart failure through a generous endowment from the Mathews Center for Cellular Therapy at Northwestern Medicine.